Reviewing Pressure BioSciences (OTCMKTS:PBIO) & enVVeno Medical (NASDAQ:NVNO)

Pressure BioSciences (OTCMKTS:PBIO) and enVVeno Medical (NASDAQ:NVNO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Pressure BioSciences and enVVeno Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pressure BioSciences	0	0	0	0	0.00
enVVeno Medical	1	1	0	0	1.50

Volatility & Risk

Pressure BioSciences has a beta of -0.14, meaning that its share price is 114% less volatile than the S&P 500. Comparatively, enVVeno Medical has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.

Profitability

This table compares Pressure BioSciences and enVVeno Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pressure BioSciences	N/A	N/A	N/A
enVVeno Medical	N/A	-61.45%	-56.88%

Institutional & Insider Ownership

0.0% of Pressure BioSciences shares are owned by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are owned by institutional investors. 10.8% of Pressure BioSciences shares are owned by company insiders. Comparatively, 15.0% of enVVeno Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Pressure BioSciences and enVVeno Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pressure BioSciences	$1.98 million	0.01	-$29.31 million	($0.96)	0.00
enVVeno Medical	N/A	N/A	-$21.82 million	($37.89)	-0.26

enVVeno Medical has lower revenue, but higher earnings than Pressure BioSciences. enVVeno Medical is trading at a lower price-to-earnings ratio than Pressure BioSciences, indicating that it is currently the more affordable of the two stocks.

About Pressure BioSciences

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.